Cargando…
S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
Autores principales: | Kenet, Gili, Nolan, Beatrice, Zulfikar, Bulent, Antmen, Bulent, Kampmann, Peter, Matsushita, Tadashi, You, Chur-Woo, Vilchevska, Kateryna, Bag, Catherine N., Sharif, Azizan, Peyvandi, Flora, Young, Guy, Negrier, Claude, Sussebach, Christian, Shammas, Fadi, Andersson, Shauna, Mei, Baisong, Kavakli, Kaan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428383/ http://dx.doi.org/10.1097/01.HS9.0000968124.64352.6e |
Ejemplares similares
-
S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023) -
Gene therapy in haemophilia: literature review and regional perspectives for Turkey
por: Kavaklı, Kaan, et al.
Publicado: (2022) -
Antithrombin lowering in hemophilia: a closer look at fitusiran
por: Young, Guy, et al.
Publicado: (2023) -
Management of haemophilia A with inhibitors: A regional cross‐talk
por: Peyvandi, Flora, et al.
Publicado: (2022) -
Evaluation of Unfavorable Cardiovascular and Metabolic Risk Factors in Children and Young Adults with Haemophilia
por: Yıldız, Melek, et al.
Publicado: (2019)